ANI Pharmaceuticals saw its stock rise following successful Phase 4 clinical trial results for an implant improving vision in a chronic eye condition. Despite the positive news, insiders including the Senior VP and CFO sold shares recently after the stock price increased. The company plans to present full trial results at a future medical meeting. ANI Pharmaceuticals currently trades around $80.55 per share with a market cap of $1.83 billion.
Fastenal Company reported earnings per share of $0.33, surpassing analyst expectations of $0.32, and revenue of $2.39 billion, exceeding estimates of $2.34 billion. The company saw strong sales growth fueled by favorable pricing and a 16.2% increase ...
Johnson & Johnson is set to report its Q2 2026 earnings with analysts expecting earnings per share of $2.85 and revenue of $25.02 billion, both higher than the previous year. The company has a strong track record of beating revenue estimates and its ...
MKS Inc., a global technology provider, has been recognized by U.S. News & World Report as one of the 2026-2027 Best Companies to Work For, ranking highly in the Manufacturing and Agriculture Industries category. This marks the fourth consecutive yea...
Citigroup reported Q2 2026 earnings that surpassed analyst expectations, with revenue of $24.77 billion and earnings per share of $3.15, exceeding forecasts of $23.74 billion and $2.74 EPS. The strong performance was fueled by robust trading and inve...
Sperax, creator of the auto-yield stablecoin USDs and SperaxOS AI agent workspace, has become an official IBM Business Partner. This partnership combines Sperax's AI-driven DeFi technology with IBM's enterprise AI and cloud infrastructure, enabling r...
